Strategy
Provided a drug company with payer, provider, and channel perspectives on the adoption of follow-on biologics in the United States; developed price and penetration scenarios for both biosimilars and "true" biogenerics
|
Created a supply chain strategy, manufacturing resource model, and "Make vs. Buy" outsourcing business process for a drug company with >30 NCEs in development
|
Helped a biopharmaceutical firm define and value its growth options; conducted market research and simulated (with valuation) development portfolio, market, and partnership scenarios
Evaluated and recommended drug products for development as line extensions or difficult-to-formulate generics for a drug delivery technology business
|
Defined and valued medical device and drug-device new product development opportunities in the cardiovascular, orthopaedic, oncology, tissue engineering, and wound care areas
|
Defined growth strategies in biologic manufacturing, contract research, dosage form manufacturing and packaging, excipients, and fine chemicals